Global Finance News
02 Feb 2026, 17:15
IDEXX Laboratories reported strong fourth-quarter and full-year 2025 results, highlighting double-digit growth across key metrics and a positive outlook for 2026. Fourth-quarter revenue rose 14% year over year to $1.09 billion, driven by robust Companion Animal Group diagnostics demand and record instrument placements, while EPS increased 18% to $3.08, supported by operating margin expansion.
For the full year, revenue reached $4.30 billion, up 10%, and EPS climbed 23% to $13.08. The company also issued initial 2026 guidance, forecasting revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, reflecting continued momentum in diagnostics, innovation-driven growth, and further margin improvement.
For the full year, revenue reached $4.30 billion, up 10%, and EPS climbed 23% to $13.08. The company also issued initial 2026 guidance, forecasting revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, reflecting continued momentum in diagnostics, innovation-driven growth, and further margin improvement.
